ScreenerHero

NYKD Nykode Therapeutics AS

OSL · NO · Healthcare · Biotechnology · nykode.com
3.595NOK+3.45%Mkt Cap: 131.58M $P/E: —

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap131.58M USD
Enterprise Value102.05M USD
Revenue (TTM)43.37K USD
Gross Profit43.37K USD
Net Income (TTM)-1.14M USD
Revenue/Share0.0010 NOK
Last Price3.595 NOK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees59
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010714785
Valuation
P/E (Trailing)—
P/E (Forward)534.62
PEG—
EV/EBITDA-40.53
EV/Revenue2352.89
P/S2932.38
P/B1.47
EPS (TTM)-0.59
EPS (Forward)0.01
52W Range
1.58356% of range5.170
52W High5.170 NOK
52W Low1.583 NOK
Profitability
Gross Margin100.00%
Oper. Margin-6363.21%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-13.37%
ROA-12.25%
Growth
Revenue Growth-46.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.75M USD
CapEx (TTM)3.55K USD
FCF Margin-3421.66%
FCF Yield-1.13%
Net Debt-4.02M USD
Net Debt/EBITDA1.60
Balance Sheet
Debt/Equity0.03
Current Ratio11.52
Quick Ratio11.52
Book Value/Sh2.37 NOK
Cash/Share0.14 NOK
Dividends
Fwd Div Rate1.00 NOK
Trail. Div Rate0.00 NOK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 27, 2025
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.250 NOK
Upside (mean)+73.9%
Target Range5.500 NOK – 7.000 NOK
5.500+73.9% to mean7.000
# Analysts2
Ownership
Shares Out.391.55M
Float214.19M
Insiders36.44%
Institutions15.35%
Technical
SMA 503.817 (-5.8%)
SMA 2003.243 (+10.8%)
Beta0.84
S&P 52W Chg14.58%
Avg Vol (30d)2.57M
Avg Vol (10d)1.26M
Technical Indicators
RSI (14)43.4
MACD-0.0963
MACD Signal-0.0350
MACD Hist.-0.0612
BB Upper4.274 NOK
BB Middle3.840 NOK
BB Lower3.406 NOK
BB Width22.58%
ATR (14)0.2028 NOK
Vol Ratio (20d)0.36x